Some use liposomal delivery systems that encapsulate the peptide in lipid spheres
ClinicalTrials.gov, the registry where any legitimate trial must appear before enrollment, returns zero studies for the compound, and no trial report exists in the PubMed literature
BPC-157: Comprehensive Clinical Profile and Molecular Analysis Introduction: The Gastric Pentadecapeptide BPC-157 (Body Protection Compound-157) represents a stable gastric pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Maximum benefits are usually achieved within 1-2 months with consistent injections
Reported risks and adverse effects associated with intravenous glutathione administration include the following: Injection site reactions: Bruising, pain, or swelling at the cannula insertion site are among the most commonly reported effects
Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections